User:Mr. Ibrahem/Primidone
Clinical data | |
---|---|
Trade names | Lepsiral, Mysoline, Resimatil, others |
Other names | desoxyphenobarbital, desoxyphenobarbitone |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682023 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Anticonvulsant (barbiturate) |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~100%[3] |
Protein binding | 25%[3] |
Metabolism | Liver |
Elimination half-life | Primidone: 5-18 h, Phenobarbital: 75-120 h,[3] PEMA: 16 h[4] Time to reach steady state: Primidone: 2-3 days, Phenobarbital&PEMA 1-4weeks[5] |
Excretion | Kidney |
Identifiers | |
| |
Chemical and physical data | |
Formula | C12H14N2O2 |
Molar mass | 218.252 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Primidone, sold under various brand names, is a medication used to treat seizures including partial and generalized seizures.[6] It may also be used for essential tremors.[7] The dose may be based on levels measured in the blood.[6] It is taken by mouth.[6]
Common side effects include sleepiness, poor coordination, nausea, and loss of appetite.[6] Severe side effects may include suicide, psychosis, a lack of blood cells.[7][6] Use during pregnancy may result in harm to the baby.[6] Primidone is an anticonvulsant of the barbiturate class.[6] How it works is not entirely clear.[6]
Primidone was approved for medical use in the United States in 1954.[6] It is available as a generic medication.[7] A month supply in the United Kingdom costs the NHS about 68.40 £ as of 2019.[7] In the United States the wholesale cost of this amount is about US$13.20.[9] In 2017, it was the 238th most commonly prescribed medication in the United States, with more than two million prescriptions.[10][11]
References[edit]
- ^ a b "Primidone (Mysoline) Use During Pregnancy". Drugs.com. 18 February 2019. Retrieved 16 May 2020.
- ^ "Primidone SERB 50mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 18 August 2014. Retrieved 16 May 2020.
- ^ a b c Ochoa, Juan G; Riche, Willise. (2005). "Antiepileptic Drugs: An Overview". eMedicine. eMedicine, Inc. Retrieved 2005-07-02.
- ^ CDER, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (2003–2005). "Primidone (Mysoline)". Pharmacology Guide for Brain Injury Treatment. Brain Injury Resource Foundation. Retrieved 2005-07-02.
- ^ Yale Medical School, Department of Laboratory Medicine (1998). "Therapeutic Drug Levels". YNHH Laboratory Manual - Reference Documents. Yale Medical School. Retrieved 2005-07-13.
- ^ a b c d e f g h i j k "Primidone Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 8 April 2019.
- ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 332. ISBN 9780857113382.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 8 September 2020.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Primidone - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.